2009
Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer.
Dominici L, Negron Gonzalez V, Buzdar A, Lucci A, Mittendorf E, Pusztai L, Krishnamurthy S, Le-Petross H, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt K, Valero V, Kuerer H. Eradication of Axillary Lymph Node Metastases Occurs in 74% of Patients Receiving Neoadjuvant Chemotherapy with Concurrent Trastuzumab for HER2 Positive Breast Cancer. Cancer Research 2009, 69: 1086-1086. DOI: 10.1158/0008-5472.sabcs-09-1086.Peer-Reviewed Original ResearchAxillary pathologic complete responseTrastuzumab-based neoadjuvant chemotherapyPathologic complete responseDisease-free survivalHER2-positive breast cancerHER2-positive diseaseResidual axillary diseaseNeoadjuvant chemotherapyPositive breast cancerAxillary metastasesPCR groupAxillary diseasePositive diseaseBreast cancerComplete axillary lymph node dissectionAxillary lymph node dissectionAxillary lymph node metastasisComplete pathologic responseLymph node dissectionKaplan-Meier methodMajority of patientsKaplan-Meier analysisLymph node metastasisEstrogen receptor statusConcurrent trastuzumab
2008
Evaluation of biological pathways involved in chemotherapy response in breast cancer
Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Research 2008, 10: r37. PMID: 18445275, PMCID: PMC2397539, DOI: 10.1186/bcr2088.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Resistance, NeoplasmE2F3 Transcription FactorFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, p53HumansKi-67 AntigenLymphatic MetastasisMiddle AgedMutationNeoadjuvant TherapyNeoplasm StagingPaclitaxelReceptors, EstrogenSignal TransductionTreatment OutcomeConceptsER-positive breast cancerPathologic complete responseER-positive cancersER-negative cancersGenomic grade indexBreast cancerChemotherapy sensitivityGene signatureER-negative breast cancerProliferation signatureER-positive patientsPositive breast cancerExpression of ERPreoperative paclitaxelProliferation gene signatureCyclophosphamide chemotherapyComplete responseResidual cancerChemotherapy responsePCR groupKi67 expressionEstrogen receptorIntroductionOur goalCancerChemotherapy